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Chronic obstructive pulmonary disease (COPD) is considered the fourth-leading causes 
of death worldwide; COPD is caused by inhalation of noxious indoor and outdoor par-
ticles, especially cigarette smoke that represents the first risk factor for this respiratory 
disorder. To mimic the effects of particulate matter on COPD, we isolated peripheral 
blood mononuclear cells (PBMCs) and treated them with combustion-generated ultraf-
ine particles (UFPs) obtained from two different fuel mixtures, namely, pure ethylene and 
a mixture of ethylene and dimethylfuran (the latter mimicking the combustion of biofuels). 
UFPs were separated in two fractions: (1) sub-10 nm particles, named nano organic 
carbon (NOC) particles and (2) primarily soot particles of 20–40 nm and their agglomer-
ates (200 nm). We found that both NOC and soot UFPs induced the release of IL-18 and 
IL-33 from unstable/exacerbated COPD-derived PBMCs. This effect was associated 
with higher levels of mitochondrial dysfunction and derived reactive oxygen species, 
which were higher in PBMCs from unstable COPD patients after combustion-generated 
UFP exposure. Moreover, lower mRNA expression of the repairing enzyme OGG1 was 
associated with the higher levels of 8-OH-dG compared with non-smoker and smokers. 
It was interesting that IL-18 and IL-33 release from PBMCs of unstable COPD patients 
was not NOD-like receptor 3/caspase-1 or caspase-8-dependent, but rather correlated 
to caspase-4 release. This effect was not evident in stable COPD-derived PBMCs. Our 
data suggest that combustion-generated UFPs induce the release of caspase-4-depen-
dent inflammasome from PBMCs of COPD patients compared with healthy subjects, 
shedding new light into the biology of this key complex in COPD.
Keywords: combustion-generated ultrafine particles, inflammation, airway disease, chronic obstructive 
pulmonary disease, peripheral blood mononuclear cells
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inTrODUcTiOn
Chronic obstructive pulmonary disease (COPD) is considered 
the fourth-leading causes of death worldwide, predicted to 
become the fifth ranked cause of disability worldwide (1). The 
development of COPD is caused by inhalation of noxious indoor 
and outdoor particles (2), especially cigarette smoke that repre-
sents the first risk factor for this respiratory disorder (3). Herein, 
chronic inflammatory pattern/s observed in the lung of COPD 
patients derives from the exposure of both cigarette smoke and 
air pollution, which affect lung resident and circulating cells (1, 
3, 4). Although, the molecular mechanisms causing inflamma-
tory patterns in COPD patients are still elusive; so far, an altered 
immune response followed by chronic inflammation has been 
described at the basis of COPD (1–3, 5, 6). Therefore, the main 
goal of our study was to understand the pro-inflammatory pattern 
induced by the exposure to ultrafine particles (UFPs) of human 
peripheral blood mononuclear cells (PBMCs) obtained from 
COPD patients, who are all former or current smokers. Over 
recent years, several papers demonstrated that oxidative stress 
due to cigarette smoking is critical for the activation of molecular 
mechanisms, such as NF-kB activation, that can lead to the 
release of pro-inflammatory mediators (3). In the milieu of pro-
inflammatory mediators, IL-1-like cytokines have been detected 
in both sputum and bronchoalveolar lavage fluid of COPD 
patients (1) and of experimental murine models (7–9). It has been 
observed that biomass fuel smoke induces the activation of the 
inflammasome, a multimeric complex, that leads to the release of 
IL-1-like cytokines, which are responsible of early inflammation 
and that can result in a long-term chronic inflammation (10). 
Emerging evidence suggests that NOD-like receptor 3 (NLRP3) 
inflammasome may be involved in COPD pathogenesis (1). We 
previously demonstrated that ultrafine carbonaceous particulate 
matter (UFP) generated in very fuel-rich combustion conditions 
(mean sizes of 100 nm) triggered NLRP3/caspase-1-dependent 
inflammasome in smoker-derived PBMCs (11). To date, high 
levels of IL-1β are found in the lungs of patients with COPD after 
cigarette smoke exposure, implying the involvement of the inflam-
masome in this pathology. In support, several cigarette exposure 
COPD animal models showed that the genetic absence of both 
caspase-1, the enzyme involved in the canonical inflammasome 
complex, and NLRP3 reduced COPD-like features in mice (8, 9, 
12), and this observation was further confirmed by neutralization 
of IL-1β (13). However, published experimental data on human 
samples from COPD patients are controversial in this regard (1). 
While several clinical studies have shown that IL-1-like cytokine 
levels are elevated in the lungs of patients with COPD (1), oth-
ers found no correlation between NLRP3, caspase-1, and IL-1β 
responses when comparing stable COPD patients to smokers 
(14). Nevertheless, the latter study was performed on a cohort of 
stable COPD patients compared with healthy smokers. Di Stefano 
et al. proposed that, rather, the inflammasome complex could be 
relevant during COPD exacerbations (15).
In this article, we analyzed the effect of UFPs representative of 
those encountered in practical combustion conditions, including 
gasoline and diesel engines, and we found that PBMCs obtained 
from unstable/exacerbated COPD patients were able to solely 
release IL-18 and IL-33, but not IL-1α and IL-1β, when treated 
with combustion-formed UFPs. By contrast, PBMCs obtained 
from smoker and non-smoker healthy volunteers were less sus-
ceptible than unstable COPD-derived PBMCs to biofuel-like UFP 
exposure. Moreover, this effect was not dependent on NLRP3, 
caspase-1, and caspase-8, but rather on the release of caspase-4, 
implying the involvement of the non-canonical inflammasome 
pathway in PBMCs obtained from unstable/exacerbated COPD 
patients. By contrast, PBMCs obtained from stable COPD patients 
were not affected by the exposure to this particulate matter in 
terms of IL-18 and IL-33 release.
MaTerials anD MeThODs
human samples
Blood from COPD and non-COPD subjects were collected at 
the Hospital “Monaldi-Azienda Ospedaliera (AORN)-Ospedale 
dei Colli” in Naples, Italy, after signed informed consent. The 
experimental protocol was performed in accordance with 
the guidelines and regulations provided and accepted by the 
Ethical Committee of the “Monaldi-AORN-Ospedale dei Colli” 
Hospital (approval number 1254/2014). COPD and non-COPD 
subjects were 60  ±  10 (mean  ±  SEM) years of age. COPD 
subjects were smokers or former smokers; non-COPD subjects 
were divided in smokers and non-smokers. Blood was collected 
and used within 24 h.
isolation of human PBMcs
Mononuclear cells were isolated according to Ficoll’s protocol 
as already reported (11). Briefly, blood (5  ml) was mixed with 
cell medium (5 ml) supplemented with sole antibiotics and Ficoll 
medium (Life Sciences, Italy). PBMC layer was collected, and 
platelets were separated by centrifugation at 150  g for 10  min. 
PBMCs were then collected in cell medium, plated (105 cells/well) 
and treated for 1, 3, or 5 h, accordingly. Treatment was performed 
in duplicate for each patient. Experimental time points were 
repeated for each patient.
Preparation of UFPs
Ultrafine particles were collected from laboratory premixed 
flames, which were run in fuel-rich conditions feeding ethylene/
air and ethylene-2,5-dimethylfuran/air mixtures with an equiva-
lence ratio of 2.0 and divided in two parts according to their sizes: 
sub-10 nm particles and larger soot particles (16).
Sub-10 nm particles were mostly constituted of organic car-
bon (17). They were stacks of few aromatic molecules, which had 
high-molecular mass and were constituted by four to six fused 
benzene rings with a dimension of about 1.2 nm connected by 
chain-like bridge (van der Waals interactions).
Larger soot particles were more graphitic carbon structures 
(17); they had sizes ranging from 20–40 nm, typical of the primary 
soot particles, to 100–200  nm typical of the chain-like aggre-
gates of the primary particles: ultraviolet–visible and infrared 
spectroscopy and Raman spectroscopy were used for structural 
analysis of the carbon-network constituting the particles (18, 19). 
Soot particles appeared as a network of aromatic structures with 
TaBle 1 | Characteristics of the ultrafine particles (UFPs).
UFP characteristics
name Fuel Particle size h/c 
atomic
% O aromatic 
domain 
dimension
NOC-E Ethylene sub-10 nm 0.6–0.8 n.d. 1.0–1.2 nm
NOC-ED Ethylene/2,5 
DMF (80/20 
vol.%)
sub-10 nm 0.6–0.8 n.d. 1.0–1.2 nm
Soot-E Ethylene 20–200 nm 0.2–0.3 <1% 1.2–1.4 nm
Soot-E/
DMF
Ethylene/2,5 
DMF (80/20 
vol.%)
20–200 nm 0.2–0.3 <5% 1.2–1.4 nm
n.d., not detected; NOC, nano organic carbon; 2,5 DMF, 2,5 dimethylfuran.
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few peripheral H atoms. Elemental analysis confirmed the low 
presence of H atoms in the soot particles, as the amount of C 
was approximately 95–98%, in mass, of the total material, and H 
was approximately 1–2%, with the rest being trace compounds, 
possibly oxygen.
Sub-10 nm particles and primary soot particles and aggre-
gates were dispersed in bidistilled water to obtain a suspension 
with a concentration of 5 ppm (5 µg/ml). The mass concentra-
tions were determined assuming a density of 1.2 and 1.8 g/cm3 
for sub-10 nm and soot particles, respectively. Here, we define 
NOC-E and NOC-ED the samples of sub-10  nm particles 
collected burning ethylene and the ethylene/dimethylfuran, 
whereas Soot-E and Soot-E/DMF the larger sizes soot particles 
collected burning ethylene and the ethylene/dimethylfuran, 
respectively. A summary of the particle characteristics is 
reported in Table 1.
cytokine Measurements
IL-18 and IL-33 were measured in cell-free supernatants 
(75  ×  104  cells/well) using commercially available ELISA kits 
(eBioscience, CA, USA). No differences in cytokine release were 
observed according to stage of COPD patients. 8-OH-dG was 
measured following manufacturer’s instructions after 3 h of treat-
ment (5 × 106 cells/well) (Elabscience, USA). The release of cas-
pase-4 was analyzed by an ELISA kit patented by ImmunePharma 
s.r.l. (RM2014A000080 and PCT/IB2015/051262) (Department 
of Pharmacy, University of Salerno, Italy). According to the pat-
ent policy, and because it is still not commercially available, it is 
not at the moment possible to describe the technical approach to 
determine the release of caspase-4 by using the ImmunePharma’s 
ELISA kit.
calcium Measurement
Intracellular Ca2+ concentrations ([Ca2+]i) were measured as 
previously reported after 1  h of treatment (5 ×  103  cells/well) 
(20). Data were expressed as percentage of delta increase of fluo-
rescence ratio (F340/F380 nm) induced by ionomycin (1 µM) or 
carbonyl cyanide p-trifluoromethoxy-phenylhydrazone (FCCP, 
0.05  µM)—basal fluorescence/basal fluorescence ratio (F340/
F380 nm).
Flow cytometry
Peripheral blood mononuclear cells were stained for flow 
cytometry analysis (BD FACSCalibur Milan, Italy) using the fol-
lowing antibodies: CD14-PE and NLRP3-PeCy5.5. Healthy non-
smoker-, smoker-, and COPD-derived PBMCs (2 × 105 cells/well) 
were stained for MitoSOX Mitochondrial Superoxide Indicator as 
indicated in the manufacturer’s guide (Life Technologies, USA).
rT-Pcr
Total RNA was isolated from PBMCs (107 cells/well) by using the 
RNA extraction kit (Qiagen, Milan, Italy). Reverse Transcription 
was performed by using first-strand cDNA synthesis kit (Qiagen, 
Milan, Italy) followed by PCR. Thermal cycling conditions were 
as follow:
 1. 5 min at 95°C, followed by 40 cycles of 30 s at 95°C, 60 s at 
54°C, 30 s at 60°C for OGG1.
 2. 5 min at 95°C, followed by 40 cycles of 30 s at 95°C, 60 s at 
58°C, 30 s at 68°C for caspase-4.
Primer pairs were as follow:
OGG1: Forward 5′-GACAAGACCCCATCGAATGC-3′
Reverse 5′-AGCTTCCTGAGATGAGCCTC-3′
CASPASE-4: Forward 5′-TCCCTGGGCAAAGATTTCCT-3′
Reverse 5′-GTCCAGCCTCCATATTCGGA-3′
β-actin: Forward 5′-ACTCTTCCAGCCTTCCTTCC-3′
Reverse 5′-CGTACAGGTCTTTGCGGATG-3′
statistical analysis
Data are reported as median  ±  interquartile range or as 
mean ± SEM. Statistical differences were assessed with one-way 
analysis of variance followed by Bonferroni’s multiple comparison 
post test, and p values less than 0.05 were considered significant.
resUlTs
combustion-generated UFPs induced the 
release of il-18 from human PBMcs 
Obtained from Unstable cOPD Patients
To mimic environmental pollution, PBMCs were isolated from 
smokers, non-smokers, and COPD patients, and then treated 
with two classes of combustion-generated UFPs for 5 h. Figure 1 
reports the release of IL-18 after the addition of Soot-E (A), 
Soot-E/DMF (B), NOC-E (C), and NOC-ED (D) at concentra-
tions of 50 and 100 pg/ml. Clearly, UFPs induced the release of 
IL-18 from PBMCs obtained from unstable exacerbated COPD 
patients (black bars, Figure 1). To note, the release of IL-18 from 
PBMCs of unstable/exacerbated COPD patients was significantly 
higher than that observed from PBMCs of non-smoker (Figure 1, 
white bars) and smoker (Figure  1, dotted bars) volunteers. 
Noticeably, Soot-E (Figure 1A) and Soot-E/DMF (Figure 1B) did 
not induce IL-18 release from PBMCs obtained from non-smoker 
(Figures 1A,B, white bars) and smokers (Figures 1A,B, dotted 
bars), compared with the control (CTR)/basal levels.
Similarly, the same mass concentrations of NOC-E (Figures 1C) 
and NOC-ED (Figure 1D) increased the release of IL-18 from 
FigUre 1 | The administration of combustion-generated ultrafine particles (UFPs) for 5 h induced the release of IL-18 by peripheral blood mononuclear cells 
(PBMCs) obtained from unstable/exacerbated chronic obstructive pulmonary disease (COPD) patients. Healthy non-smoker (white bars), smoker (dotted bars), and 
COPD (black bars)-derived PBMCs were treated with soot combustion-derived UFPs for 5 h. The addition of Soot-E (a), Soot-E/DMF (B), nano organic carbon 
(NOC)-E (c), and NOC-ED (D) at the concentration of 50–100 pg/ml induced the release of IL-18. Control (CTR) represents untreated cells. Data are presented as 
median ± interquartile range (n = 7). Statistically significant differences were determined by one-way analysis of variance followed by Bonferroni’s multiple 
comparison posttest. **, ***, and **** represent p < 0.01, p < 0.0005, and p < 0.0001, respectively.
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PBMCs obtained from unstable COPD (Figures  1C,D, black 
bars) and were almost non-active at inducing IL-18 release from 
non-smoker- derived (white bars) and smoker-derived (dotted 
bars) PBMCs (Figures 1C,D).
The same mass concentrations of NOC and soot particles cor-
respond to different surface area of the particles exposed to cells 
due to the different sizes of the particles. In particular, 100 pg/ml 
of soot have a surface area of 2.2E−4 cm2/ml whereas the same 
amount of NOC has a surface area of 2E−3 cm2/ml, implying that 
NOC particles expose higher surface area than soot particles, due 
to their lower size. To verify, whether the size of these sub-10 nm 
particles was a limitation, we treated cells with coronene and 
5De Falco et al. UFPs Trigger Caspase-4 in COPD Patients
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pyrene, polycyclic aromatic hydrocarbons with sizes comparable 
to those measured for the aromatic compounds that constitute 
the nanoparticles (1 pg/ml up to 1 ng/ml). As shown in Figures 
S1A–C in Supplementary Material, both coronene and pyrene 
(10 pg/ml) significantly increased IL-18 release from PBMCs of 
non-smokers (Figure S1A in Supplementary Material), smokers 
(Figure S1B in Supplementary Material), and unstable COPD 
(Figure S1C in Supplementary Material) at 10 pg/ml correspond-
ing to 6E−4 cm2, implying that the size of the particles was not 
as relevant as the nature of the particles. Moreover, similarly to 
NOC-E and NOC-ED particles, we observed that cells were more 
responsive to the lower concentrations than the higher (data not 
shown), reaching a plateau at 10 pg/ml. Interestingly, PBMCs from 
non-smokers (Figure S1A in Supplementary Material) and smok-
ers (Figure S1B in Supplementary Material) were less responsive 
in terms of IL-18 release compared with PBMCs obtained from 
unstable COPD patients (Figure S1C in Supplementary Material), 
which instead showed a significant increase. These data underlie 
that the organic nature of UFPs, as well as soot and NOC, is of 
relevant importance for cell responsiveness in terms of IL-18 
release.
combustion-generated UFPs induced the 
release of il-33 from human PBMcs 
Obtained from Unstable/exacerbated 
cOPD Patients
Similarly to what performed for IL-18, we treated PBMCs from 
the three cohorts with soot and NOC UFPs. The addition of 
Soot-E (Figure  2A), Soot-E/DMF (Figure  2B, black bars), 
NOC-E (Figure 2C, black bars), and NOC-ED (Figure 2D, black 
bars) significantly increased the release of IL-33 at the concen-
tration of 50–100 pg/ml from PBMCs obtained from unstable/
exacerbated COPD patients. Also in this case, we observed that 
IL-33 release reached a plateau at 50–100 pg/ml whereas at higher 
concentrations of these UFPs (>100 pg/ml up to 1 ng/ml, data not 
shown) no increasing effect was observed. However, it is to note 
that despite what happened for IL-18, no statistical increase of 
IL-33 release was observed comparing results among the groups 
represented by non-smokers (Figure  2, white bars) and smok-
ers (Figure 2, dotted bars). Instead, the stimulation of PBMCs 
derived by unstable COPD patients with Soot-E (Figure  2A, 
black bars), Soot-ED (Figure 2B, black bars), NOC-E (Figure 2C, 
black bars), and NOC-ED (Figure 2D, black bars) increased the 
levels of IL-33. It is to note, though, that we observed a statistical 
difference in IL-33 basal levels that were higher in smokers than 
unstable COPD-derived PBMCs (Figure 2, dotted bars vs black 
bars).
combustion-generated UFPs increased 
Oxidative stress in human PBMcs 
Obtained from Unstable/exacerbated 
cOPD Patients
In our previous study, we demonstrated that the release of IL-1-
like cytokines after UFP exposure was caspase-1- and NLRP3 
inflammasome dependent in PBMCs from healthy smokers (11). 
To understand the molecular mechanism underlying the release 
of IL-18 and IL-33 from unstable COPD patients after organic 
UFP exposure, we carried on evaluating the role of NLRP3 and 
mitochondrial-dependent oxidative stress. We observed that the 
expression of NLRP3 in CD14+ PBMCs in basal conditions was 
significantly higher in COPD patients (Figure 3A, black bars) than 
non-smokers (Figure 3A, white bars) and smokers (Figure 3A, 
dotted bars). Similarly, mitochondrial-derived reactive oxygen 
species (mtROS) (identified as % Mitosox cells) were robustly 
higher in PBMCs from unstable/exacerbated COPD patients 
than non-smokers and smokers (Figure 3B). Starting from these 
observations and based on the concept that NLRP3 activation 
is strictly dependent on mtROS production (21), we measured 
mitochondria homeostasis under UFP treatment. The exposure 
to UFPs of PBMCs from non-smokers (Figure 3C, white bars) 
and smokers (Figure  3C, dotted bars) increased the release of 
calcium (Ca+2) from mitochondria only after an external stimulus 
(carbonyl cyanide p-trifluoromethoxy-phenylhydrazone, FCCP) 
during the measurement/detection, implying that UFP treatment 
did not alter mitochondrial calcium stores. By contrast, the meas-
urement of Ca+2 stores in the mitochondria of unstable COPD-
derived PBMCs were lower (Figure 3C, black bars) than those 
observed in non-smokers and smokers (Figure  3C, white and 
dotted bars) after Soot-E, Soot-E/DMF, NOC-E, and NOC-ED 
(100 pg/ml) treatment. The above data imply that the stimulation 
of PBMCs with these particles had already induced the release of 
Ca+2 from the mitochondria in unstable COPD-derived PBMCs. 
Because the release of Ca+2 from the mitochondria is strictly cor-
related to the release of mtROS (20) and protein/DNA damage, 
the levels of 8-hydroxy-deoxyguanosine (8-OH-dG), a well-
known marker for DNA damage derived from oxidative stress 
(22), were measured. Very interestingly, the addition of NOC-E 
and NOC-ED significantly increased the release of 8-OH-dG in 
non-smoker (Figure 3D, white bars) and smokers (Figure 3D, 
dotted bars). However, 8-OH-dG release was more pronounced 
in PBMCs from unstable/exacerbated COPD patients after the 
addition of Soot-E/DMF, NOC-E, and NOC-ED (100  pg/ml) 
(Figure 3D, black bars).
To note, we did not observe a significant increase in mtROS 
from non-smokers after the addition of all particle samples 
(Soot-E, Soot-E/DMF, NOC-E, and NOC-ED, each 100 pg/ml) 
compared with smokers and COPD PBMCs (data not shown). 
Therefore, we went on to analyze the levels of a repairing enzyme, 
8-oxoguanine glycosylase, OGG1, highly important to avoid 
DNA damage following oxidative stress (23). The administra-
tion of all UFPs (100  pg/ml) significantly increased the levels 
of mRNA in PBMCs obtained from non-smokers (Figure  3E, 
white bars). By contrast, PBMCs from smokers did not show any 
increase compared with the basal levels of mRNA for OGG1 after 
all UFP (100 pg/ml) exposure (Figure 3E, dotted bars), but rather, 
a significant decrease was observed. Interestingly, PBMCs from 
unstable COPD patients showed no increase of OGG1 mRNA 
levels after Soot-E, Soot-E/DMF, NOC-E, and NOC-ED (100 pg/
ml) exposure (Figure 3E, black bars).
These data imply that treatment of PBMCs obtained from 
unstable/exacerbated COPD patients with Soot-E, Soot-E/DMF, 
NOC-E, and NOC-ED leads to mitochondrial dysfunction in that 
FigUre 2 | The administration of combustion-generated ultrafine particles (UFPs) for 5 h induced the release of IL-33 by peripheral blood mononuclear cells 
(PBMCs) obtained from unstable/exacerbated chronic obstructive pulmonary disease (COPD) patients. Healthy non-smoker (white bars), smoker (dotted bars), and 
COPD (black bars)-derived PBMCs were treated with soot combustion-derived UFPs for 5 h. The addition of Soot-E (a), Soot-E/DMF (B), NOC-E (c), and NOC-ED 
(D) at the concentration of 50–100 pg/ml induced the release of IL-33. Control (CTR) represents untreated cells. Data are presented as median ± interquartile range 
M (n = 7). Statistically significant differences were determined by one-way analysis of variance followed by Bonferroni’s multiple comparison posttest. *, **, §, and §§ 
represent p < 0.05, p < 0.01, p < 0.005, and p < 0.001, respectively.
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oxidative stress occurs. In this context, however, this effect is not 
countered by repairing enzymes, such as OGG1, establishing a 
pro-inflammatory/prooxidative cytoplasmic molecular pattern 
that leads to the release of IL-18 and IL-33 from PBMCs obtained 
from unstable/exacerbated COPD patients.
The release of il-18 and il-33 from 
Unstable cOPD-Derived PBMcs is not 
nlrP3/caspase-1-Dependent after 
combustion-generated UFP exposure
Because the release of mtROS and the presence of 8-OH-dG 
are able to induce the activation of NLRP3 inflammasome 
and because we found that NLRP3 protein levels are higher in 
unstable COPD patients, we went on by analyzing the molecular 
mechanism underlying the release of IL-18 and IL-33 from 
unstable COPD-derived PBMCs after combustion-generated 
UFP exposure. Therefore, unstable COPD-derived PBMCs were 
treated with pharmacological inhibitors for caspase-1, ac-Y-Vad 
(Y-Vad, 1  µg/ml) (20), for NLRP3, glybenclamide (Gly, 1  µM) 
(11, 20) and for caspase-8, z-IETD-fmk (IE, 0.5 µg/ml) (24, 25) 
together with combustion-generated UFPs.
The pharmacological inhibition of caspase-1 did not alter the 
levels of IL-18 from unstable COPD-derived PBMCs after Soot-E 
(Figure 4A), Soot-E/DMF (Figure 4B), NOC-E (Figure 4C), or 
NOC-ED (Figure  4D) exposure. In support, the inhibition of 
NLRP3 by means of Gly did not affect the levels of IL-18 from 
unstable COPD-derived PBMCs after Soot-E (Figure  4A), 
FigUre 3 | The administration of combustion-generated ultrafine particles (UFPs) induced mitochondria-dependent oxidative stress. Healthy non-smoker (white 
bars), smoker (dotted bars), and chronic obstructive pulmonary disease (black bars)-derived peripheral blood mononuclear cells (PBMCs) were treated with soot 
combustion-derived UFPs for 5 h. Levels of NOD-like receptor 3 (NLRP3) inflammasome (a) in CD14+ PBMCs and mitochondria-derived reactive oxygen species 
(mtROS), identified as Mitosox+ cells determined by means of flow cytometry (B). (c) Levels of mitochondrial Ca+2 stores after the addition of Soot-E, Soot-E/DMF, 
nano organic carbon (NOC)-E, and NOC-ED at the concentration of 100 pg/ml for 1 h. (D) Levels of cytoplasmic 8-OH-dG after 3 h of treatment of PBMCs with 
Soot-E, Soot-E/DMF, NOC-E, and NOC-ED at the concentration of 100 pg/ml. (e) Levels of mRNA levels of OGG1 after 3 h of treatment of PBMCs with Soot-E, 
Soot-E/DMF, NOC-E, and NOC-ED at the concentration of 100 pg/ml, determined by means of RT-PCR. Control (CTR) represents untreated cells. Data are 
presented as median ± interquartile range (a,B) and means ± SEM (c–e) (n = 7). Statistically significant differences were determined by one-way analysis of variance 
followed by Bonferroni’s multiple comparison posttest. *, **, §, ***, and **** represent p < 0.05, p < 0.01, p < 0.001, p < 0.0005, and p < 0.0001, respectively.
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Soot-E/DMF (Figure  4B), NOC-E (Figure  4C), or NOC-ED 
(Figure 4D) exposure. Moreover, the pharmacological inhibition 
of caspase-8, another enzyme involved in the non-canonical 
inflammasome-dependent pathway (26), did not alter IL-18 
levels (Figures 4A–D).
The same results were obtained for IL-33, where we observed 
that neither the inhibition of caspase-1 (Figures  5A–D) nor 
the inhibition of NLRP3 and caspase-8 (Figures 5A–D) altered 
the levels of the cytokine released from PBMCs obtained from 
unstable COPD patients exposed to combustion-generated UFPs.
The exposure of Unstable cOPD-Derived 
PBMcs to combustion-generated UFPs 
induced the release of caspase-4
Non-canonical inflammasome was also described as caspase-
4-dependent in humans (caspase-11 in mice) (26). However, 
FigUre 4 | The release of IL-18 from chronic obstructive pulmonary disease (COPD) peripheral blood mononuclear cells (PBMCs) treated with combustion-
generated ultrafine particles (UFPs) was not NOD-like receptor 3 (NLRP3)/caspase-1 and caspase-8-dependent. COPD (black bars)-derived PBMCs were treated 
with soot combustion-derived UFPs for 5 h in the presence of y-Vad, caspase-1 inhibitor (1 µg/ml), glybenclamide (Gly), NLRP3 inhibitor (1 µM), and IE (0.5 µg/ml) 
a caspase-8 inhibitor. The levels of IL-18 after (a) Soot-E, Soot-E/DMF (B), nano organic carbon (NOC)-E (c), and NOC-ED (D) treatment was not reduced in the 
presence of Y-Vad, Gly, and IE. Data are presented as the means ± SEM (n = 7). Statistically significant differences were determined by one-way analysis of variance 
followed by Bonferroni’s multiple comparison posttest. *, **, ***, and **** represent p < 0.05, p < 0.01, p < 0.0005, and p < 0.0001, respectively.
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caspase-11 was defined as inducible, not constitutive, in mice (27). 
Therefore, we first analyzed the levels of mRNA for caspase-4 in 
PBMCs obtained from unstable COPD patients.
We found that caspase-4 mRNA levels were detectable in 
CTR cells and, interestingly, the treatment of cells with NOC-ED 
significantly increased caspase-4 mRNA levels (Figure 6A). To 
evaluate the potential involvement of caspase-4 in UFP effects, 
we used a patented ELISA kit (as described in Section “Materials 
and Methods”). Very interestingly, the addition of NOC-ED 
significantly increased the release of caspase-4 from PBMCs 
obtained by unstable COPD patients (Figure 6B). However, we 
were not able to reach a statistical difference when cells were 
treated with the other three UPFs samples, Soot-E or Soot-E/
DMF or NOC-E (Figure 6B). Nevertheless, a potential increase 
was observed: 0.61  ±  0.32  ng/ml for Soot-E (100  pg/ml) vs 
0.35 ± 0.09 ng/ml for CTR; 1.36 ± 0.74 ng/ml for NOC-E (100 pg/
ml) vs 0.35 ± 0.09 ng/ml for CTR. Similar data were observed 
when COPD-derived PBMCs were treated with coronene (10 pg/
ml; 1.74 ± 0.7 ng/ml).
Taken together, these data imply the extracellular release of 
caspase-4 and its involvement in IL-18 and IL-33 increase when 
PBMCs obtained from unstable COPD patients are treated with 
UFPs.
DiscUssiOn
In this study, we found that combustion-generated UFPs induced 
mitochondrial-derived oxidative stress, which is not countered by 
the enzyme OGG1, deputed to repairing oxidative stress damage, 
leading to the release of IL-18 and IL-33 from PBMCs obtained 
from unstable/exacerbated COPD patients. Importantly, the 
release of IL-18 and IL-33 was not dependent on the activation of 
the canonical, caspase-1-dependent, and non-canonical, caspase-
8-dependent, inflammasome pathway but rather on the release 
of the caspase-4, which activity still remains to be defined after 
UFP exposure. By contrast, PBMCs obtained from stable COPD 
patients were not affected by the exposure to this particulate 
 matter in terms of IL-18 and IL-33 release.
Literature data report that high levels of IL-1β and IL-18 are 
usually found in the lungs of patients with COPD after cigarette 
smoke exposure, implying the involvement of the inflamma-
some in this pathology (1, 7, 13). In support, the adaptor protein 
ASC was found at high levels and in a speck-like form in the 
sputum of COPD patients (12). Experimental COPD animal 
models showed that the genetic absence of both caspase-1, the 
enzyme involved in the canonical inflammasome complex, and 
NLRP3 reduce COPD-like features in mice exposed to cigarette 
FigUre 5 | The release of IL-33 from chronic obstructive pulmonary disease (COPD) peripheral blood mononuclear cells (PBMCs) treated with combustion-
generated ultrafine particles (UFPs) was not NOD-like receptor 3 (NLRP3)/caspase-1 and caspase-8-dependent. COPD (black bars)-derived PBMCs were treated 
with soot combustion-derived UFPs for 5 h in the presence of y-Vad, caspase-1 inhibitor (1 µg/ml), glybenclamide (Gly), NLRP3 inhibitor (1 µM). and IE (0.5 µg/ml) a 
caspase-8 inhibitor. The levels of IL-33 after (a) Soot-E, Soot-E/DMF (B), nano organic carbon (NOC)-E (c), and NOC-ED (D) treatment was not reduced in the 
presence of Y-Vad, Gly, and IE. Data are presented as the means ± SEM (n = 7). Statistically significant differences were determined by one-way analysis of variance 
followed by Bonferroni’s multiple comparison posttest. *, **, §, and §§ represent p < 0.05, p < 0.01, p < 0.005, and p < 0.001, respectively.
9
De Falco et al. UFPs Trigger Caspase-4 in COPD Patients
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1415
smoking (5, 9, 10, 12), further confirmed by neutralization of 
IL-1β. However, published data on human samples from COPD 
patients are controversial in that no correlation between NLRP3, 
caspase-1, and IL-1β responses was observed when comparing 
stable COPD patients with smokers (1). These data imply that 
the inflammasome is not triggered in these clinical conditions, 
probably explaining the discrepancy in literature and the unsuc-
cessful randomized clinical trials performed on stable COPD 
patients subjected to canakinumab (monoclonal antibody 
against IL-1β) or an anti-P2X7 antagonist (1). To note, most of 
the human studies were performed on stable COPD-derived 
samples. In sharp contrast, our study was focused on PBMCs 
from unstable/exacerbated COPD patients, and we found that 
the sole IL-18 and IL-33, but not IL-1α and IL-1β (undetectable), 
were released after the exposure to combustion-generated UFPs. 
Instead, stable COPD-derived PBMCs were not responsive to 
combustion-generated UFPs in terms of IL-18 and IL-33 release 
(data not shown). This is, to the best of our knowledge, the first 
study showing that unstable COPD-derived PBMCs were able to 
release IL-1-like cytokines in a non-canonical inflammasome-
dependent manner after combustion-generated UFPs exposure. 
In support, as proposed by Di Stefano et al., NLRP3, Caspase-1 
and IL-1β responses in exacerbated/unstable COPD patients 
would be relevant (15). We found that although, the higher levels 
of NLRP3 in the PBMCs of these patients, it was not involved 
in the release of IL-18 and IL-33 after combustion-generated 
UFP exposure. However, in our previous study, we found that 
the stimulation of smoker-derived PBMCs with pyrolytic 
combustion-derived UFPs released higher IL-1-like cytokines 
in a NLRP3-dependent manner (11). Because all the PBMCs we 
used were obtained from smoking or former smoking COPD 
patients, we expected that NLRP3 inflammasome was most likely 
leading to the chronic inflammatory response typical of COPD 
after combustion-generated UFP exposure. Instead, we found 
that smokers were less responsive to combustion-generated UFPs 
than COPD patients, implying that the nature of air pollutants is 
of great relevance. Moreover, it is likely that although the higher 
levels, NLRP3 may be impaired in PBMCs of unstable COPD 
patients (11, 15), explaining the discrepancies in the literature. 
Indeed, the pharmacological inhibition of NLRP3 by means of 
Gly did not alter IL-18 and IL-33 levels. Similarly, we did not 
observe any inhibition of these cytokines when we inhibited 
caspase-1 and caspase-8, which underlie NLRP3 activation in a 
canonical and non-canonical manner, respectively (26). It is to 
note that although the inhibition of caspase-8 did not alter IL-18 
production after UFPs addition (Figures  4A–D), we were not 
FigUre 6 | The stimulation of unstable chronic obstructive pulmonary 
disease (COPD)-derived peripheral blood mononuclear cells (PBMCs) with 
combustion-generated ultrafine particles (UFPs) induced caspase-4 release. 
COPD (black bars)-derived PBMCs were treated with soot combustion-
derived UFPs for 5 h. The levels of caspase-4 mRNA were determined (a) 
after Soot-E/DMF, nano organic carbon (NOC)-E, and NOC-ED treatment. 
The release of caspase-4 (B) was evaluated by means of a patented 
ImmunePharma’s ELISA kit. Control (CTR) represents untreated cells. Data 
are presented as the means ± SEM (a) and (B) (n = 7). Statistically 
significant differences were determined by one-way analysis of variance 
followed by Bonferroni’s multiple comparison posttest. * and ** represent 
p < 0.05 and p < 0.01, respectively.
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able to reach a statistical difference between the basal levels when 
the sole caspase-8 inhibitor was added, versus the levels of the 
cytokine when the inhibitor and UFPs were added (Figure 4D). 
This effect was not observed for IL-33 (Figure 5).
By contrast, we found that caspase-4 release occurred after 
the exposure of PBMCs obtained from unstable COPD patients 
to combustion-generated UFPs, implying its involvement in 
IL-18 and IL-33 release. It is to point out, though, that we can-
not assume by these data that caspase-4 was directly involved 
in IL-18 and IL-33 release due to the absence of a commercially 
available specific inhibitor of the sole caspase-4. Moreover, we 
have to highlight that stable COPD-derived PBMCs treated with 
combustion-generated UFPs did not induce caspase-4 release. 
Similarly we did not detect any difference compared with the 
basal conditions of release of IL-18 and IL-33 from PBMCs 
obtained from stable COPD patients treated with UFPs. These 
data further underlie the relevance of inflammasome-dependent 
mechanisms in stable vs unstable COPD patients.
Another important issue is the role of the oxidative stress in 
PBMCs from unstable COPD patients. Oxidative stress is a criti-
cal feature and key mechanism in many molecular processes dur-
ing the onset of COPD (1). Mitochondrial dysfunction leads to 
excessive production of mtROS resulting in harmful effects, such 
as damage to lipids, proteins, and DNA. In this study, we found 
that unstable COPD-derived PBMCs exposed to combustion-
generated UFPs had higher mitochondrial impairment in that 
higher levels of oxidized nucleic acids (i.e., 8-OH-dG, widely used 
as a marker), were found compared with non-smoker PBMCs. 
8-OH-dG levels in unstable COPD-derived PBMCs were even 
higher than those observed in smoker-derived PBMCs after UFP 
exposure. This effect was strictly dependent on the expression of 
OGG1, an enzyme involved in the repair of DNA damage follow-
ing mitochondrial dysfunction (23). OGG1 was not higher in the 
PBMCs of unstable COPD patients and even more important, 
it was not increased after combustion-generated UFP exposure, 
focusing on the clinical outcome/lifestyle of these patients when 
exposed to both indoor and outdoor pollution. Moreover, because 
of the strict correlation between NLRP3 activation and mtROS/
oxidized DNA derivatives, it was obvious to believe that NLRP3 
was involved. Instead, the pharmacological inhibition of NLRP3 
did not show any correlation with IL-18 and IL-33 release after 
combustion-generated UFP exposure. In this context, though, we 
have to highlight that as reported by Shimada et al. (21), 8-OH-dG 
can bind to NLRP3 avoiding the activation of the inflammasome. 
Therefore, it is likely that NLRP3 is not involved in UFP-induced 
IL-18 and IL-33 release because of its inhibition by 8-OH-dG. 
More importantly, we found that caspase-4 is released into cell-
free supernatant. The biological role of the released caspase-4 
from unstable COPD-derived PBMCs is still under-investigated, 
and it still remains to investigate how caspase-4 is involved in 
IL-18 and IL-33 levels from PBMCs of unstable COPD patients.
In conclusion, our study highlights a novel molecular mecha-
nism by which combustion-generated nanoparticles induce the 
release of the pro-inflammatory IL-18 and IL-33 in a non-canon-
ical caspase-4-dependent inflammasome pathway from PBMCs 
of unstable/exacerbated COPD patients. Our study opens new 
perspectives in the field of the inflammasome in COPD during 
the exacerbation of clinical conditions, when the active form of 
caspase-4 is more relevant after cigarette smoke and air pollution 
exposure, paving the way for alternative pathways to be pharma-
cologically triggered in COPD pathogenesis.
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FigUre s1 | The stimulation of healthy non-smoker [white bars (a)], smoker 
[dotted bars (B)], and chronic obstructive pulmonary disease [black bars (c)] 
with coronene (10 pg/ml) or pyrene (10 pg/ml) induced the release of IL-18. 
Control (CTR) represents untreated cells. Data are presented as the 
means ± SEM (n = 7). Statistically significant differences were determined by 
one-way analysis of variance followed by Bonferroni’s multiple comparison 
posttest. * represents p < 0.05.
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